Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Pharma/biotech deals

<< Previous

Bullboard Posts

Next >>

Comment by Wino115on Oct 26, 2021 10:43am

112 Views

Post# 34049550

RE:Pharma/biotech deals

Some good points on what is attractive - I like the worldwide rights and backup molecules. I guess THTX sort of has a backup molecule is you think attaching a different chemo is a backup. Maybe their lab is developing other peptides for other targets. I'm not sure they'd count the NASh asset as a "backup".

These are RBC bankers -- you'd think the last kind thing Brian Abrahms could have done when he discontinued coverage was to introduce his oncology analyst to them and these bankers. If TH1902 comes to fruition, the discontinuation and not moving it over to the new analyst will be rather embarassing. Maybe they'll pick it up, but not sure THTX management seems to have moved on from RBC after not getting much love.

qwerty22 wrote: I thought this Q&A was interesting. THTX's cancer program ticks some of the boxes.

https://endpts.com/sp/biotech-and-big-pharma-a-blueprint-for-a-successful-partnership/